Fig. 3From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese populationKaplan-Meier analysis of progression-free survival in second and third line treatment population (a) PFS in all patients (b) PFS in the primary resistant populationBack to article page